AMSTERDAM, February 22, 2017 /PRNewswire/ --
- Developed in collaboration with leading hospitals worldwide, Philips Azurion is an innovative image-guided therapy platform that allows clinicians to easily and confidently perform a wide range of routine and complex procedures, helping them to optimize interventional lab performance and provide superior care
- Azurion is powered by ConnectOS, Philips' newly developed operating system to optimize system integration which features an easy-to-use intuitive user interface combined with real-time information on multiple work spots within the interventional lab
Royal Philips (NYSE: PHG, AEX: PHIA), a leader in health technology, today announced the global launch of Azurion, its next generation image-guided therapy platform, which forms the new core of its integrated solutions portfolio for the fast growing image-guided therapy market. As a leader in this market, Philips offers integrated solutions comprising interventional imaging technologies and planning and navigation software combined with interventional devices - including catheters for diagnosis and therapy - and a broad range of services, all aimed at helping clinicians to provide superior care at predictable costs.
Following the acquisition of Volcano in 2015, via which Philips has become a leader in advanced catheters for diagnosis and therapy, the company is now further cementing its overall leadership in the EUR 5 billion image-guided therapy market with one of its largest global product launches in recent years. Philips' Azurion image-guided therapy platform for interventional labs is the result of a multi-year development program conducted in close collaboration with leading clinicians in the field. This next generation platform features a state-of-the-art ergonomic design with an easy-to-use intuitive user interface, enabling clinicians to swiftly and confidently perform a wide range of routine and complex procedures in the interventional lab.
With the rapid growth of image-guided therapy procedures, hospitals and health systems are increasingly faced with the need to control costs, while improving their standards of care. Azurion has been designed to address these challenges and is equipped with new workflow options and performance dashboards, as well as an upcoming range of productivity improvement services.
Azurion is Philips' next generation image-guided therapy platform and the new core of its integrated solutions portfolio. Azurion supports a full range of configurations across a broad spectrum of image-guided therapy procedures. These include configurations for high volume routine procedures and flexible configurations for advanced procedures. Harnessing vital procedural information from various sources, such as imaging systems, interventional devices, navigation tools and patient health records, Azurion provides interventional staff members with the control and information they need to perform procedures efficiently.
The Azurion platform also features over 1,000 new components, including an enhanced flat-panel detector, and Philips' newly developed ConnectOS operating system for the seamless integration of real-time information from all relevant technologies in the interventional lab. All of these components work together to deliver high image quality at ultra-low X-ray dose and real-time image processing on multiple work spots within the interventional lab. Parallel working enables the team of clinicians to complete different tasks simultaneously in the interventional lab, saving valuable time without compromising quality of care. Azurion features procedure cards that allow clinicians to pre-program routine tasks and user preferences, helping to minimize preparation errors and further reducing preparation and procedure time.
Philips has pioneered a steady stream of innovations in planning and navigation software for areas such as vascular surgery (e.g. VesselNavigator), interventional cardiology (e.g. EchoNavigator), interventional oncology (e.g. EmboGuide), and interventional neuroradiology (e.g. AneurysmFlow). All these advanced interventional tools integrate seamlessly into the Azurion platform to support the clinical workflow.
Driven by their benefits for patients and care providers, minimally-invasive therapies, such as the catheter-based treatment of certain tumors, aneurysms, obstructed blood vessels, heart rhythm disorders and defective heart valves, continue to grow fast. In addition to reduced patient trauma and shorter recovery times, such procedures also have the benefit of allowing the treatment of patients who would not be able to withstand the trauma of open surgery. However, during such procedures, clinicians cannot directly see and feel the organs they are working on. Effective imaging, measurement and navigation technologies are therefore key to guiding minimally-invasive procedures. At the heart of the interventional lab, these technologies allow identification and visualization of target organs and tissues, the operation of interventional devices, and the placement of implants, leading to improved chances of therapy success.
"For over 30 years, we've pioneered minimally-invasive treatments that help our patients get back to their daily lives," said Barry T. Katzen, MD, founder and Chief Medical Executive of the Miami Cardiac & Vascular Institute, Baptist Health South Florida (U.S.). "The imaging environment is critical to perform such procedures efficiently and effectively. As an interventionalist, we want to be in the cockpit, similar to a pilot in an airplane, where we have control of everything we need and have all the relevant functions at our finger tips. Philips' next generation image-guided therapy platform just takes it to a whole other level and allows interventionalists to accomplish the procedures quicker and more efficiently, which benefits the patient."
"As a leader in image-guided therapy, we have been driving continuous innovation to address rising patient volumes and increased procedure complexity," said Bert van Meurs, Business Leader Image Guided Therapy at Philips. "Hundreds of Philips developers, engineers and designers and dozens of our clinical partners across the world have collaborated to completely redesign the heart of our portfolio. With the launch of our new Azurion platform, which was designed to optimize system integration and lab performance, we can deliver new turnkey solutions that support our customers in maintaining high standards of quality and patient care at predictable costs."
"We are on an exciting journey to strengthen the Tampere Heart Hospital's position as a Northern European center of excellence for cardiac care," said Aki Haukilahti, Executive Vice President and CFO of Heart Hospital, Tampere University Hospital (Finland). "As part of our long-term strategic partnership with Philips, we have collaborated on a turnkey solution based on the new Azurion product family. With this solution, Philips provides us with advanced technologies and an excellent user experience, combined with services for guaranteed uptime, seamless integration into our hospital workflows, staff training and education, and enhancement of our productivity. This enables our staff to fully focus on what they do best - providing superior care to our patients."
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips' health technology portfolio generated 2016 sales of EUR 17.4 billion and employs approximately 71,000 employees with sales and services in more than 100 countries. News about Philips can be found at http://www.philips.com/newscenter.
SOURCE Royal Philips